arrow
S

Swaminathan P. Iyer

the university of texas m d anderson cancer center
H指数:59
被引数:1.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Association of PET4 Response With Outcomes of BV-CHP vs CHOP in the ECHELON-2 Trial in CD30+ Peripheral T-cell Lymphoma

PET4反应与ECHELON-2试验中CD30+外周T细胞淋巴瘤患者接受BV-CHP vs CHOP治疗的结局相关性研究

2025-08-210
OAAI
Author Correction: Allogeneic NK cells with a bispecific innate cell engager in refractory relapsed lymphoma: a phase 1 trial

作者更正: 同种异体NK细胞与双特异性先天细胞衔接器治疗难治性复发性淋巴瘤: 1期试验

2025-06-260
PRE
The OHI index predicts early mortality from organ dysfunction and survival benefit from etoposide in patients with lymphoma

OHI指数预测器官功能障碍导致的早期死亡以及淋巴瘤患者从依托泊苷中获得的生存获益

2025-04-210
OAAI
Developing Novel Cellular Therapies for Cutaneous T Cell Lymphoma (CTCL): Combining Immunopeptidomics and Endogenous T Cell (ETC) Therapy Platforms to Identify and Target Shared CTCL-Associated Antigens

开发新型细胞疗法治疗皮肤T细胞淋巴瘤(CTCL):结合免疫肽组学和内源性T细胞(ETC)治疗平台以识别并靶向共同的CTCL相关抗原

BLOOD
IF23.1
2024-11-050
PRE
Large Cell Transformation in Mycosis Fungoides & Sezary Syndrome: An Analysis of 445 Cases

在Mycosis Fungoides和Sezary Syndrome中的大细胞转化:445例分析

BLOOD
IF23.1
2024-11-050
PRE
Interim PET-Adapted De-Escalation Chemotherapy Regimen for Advanced Stage Classical Hodgkin Lymphoma Using Brentuximab Vedotin, Pembrolizumab, Doxorubicin, and Dacarbazine: Phase 2 Safety and Efficacy Study

基于Brentuximab Vedotin、Pembrolizumab、Doxorubicin和Dacarbazine的晚期经典霍奇金淋巴瘤PET适应性降级化疗方案:一项关于安全性与有效性的II期研究

BLOOD
IF23.1
2024-11-050
PRE
Outcomes after Allogeneic Stem-Cell Transplant in Patients with High-Risk Large-Cell Transformation of Mycosis Fungoides (MF-LCT)

异基因干细胞移植后高危蕈样肉芽肿大细胞转化(MF-LCT)患者的结局

BLOOD
IF23.1
2024-11-050
PRE
Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study
2024-09-012
PRE
Impact of patient demographics and neighborhood socioeconomic variables on clinical trial participation patterns for NHL

患者人口统计学和邻里社会经济变量对NHL临床试验参与模式的影响

2024-07-231
OAAI
Cytomegaloviral Infections in Recipients of Chimeric Antigen Receptor T-Cell Therapy: An Observational Study With Focus on Oncologic Outcomes
2024-07-183
OAAI
Response-adapted ultra-low-dose 4 Gy radiation as definitive therapy of gastric MALT lymphoma: a single-centre, pilot trial
2024-07-014
PRE
The CNS relapse in T-cell lymphoma index predicts CNS relapse in patients with T- and NK-cell lymphomas
2024-06-280
OAAI
Epstein-Barr-virus-positive large B-cell lymphoma associated with breast implants: an analysis of eight patients suggesting a possible pathogenetic relationship (vol 34, pg 2154, 2021)
2023-12-011
OAAI
A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma

预防性anakinra减轻大b细胞淋巴瘤患者ICANS的1期研究

2023-11-1416
OAAI
Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFNg-expressing CD8 T cells

CD19 CAR T细胞治疗后的长期血细胞减少与克隆扩增的表达IFNg的CD8 T细胞的骨髓浸润有关

2023-08-0121
OAAI